triazoles has been researched along with Anemia in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.44) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (22.22) | 29.6817 |
| 2010's | 22 (48.89) | 24.3611 |
| 2020's | 11 (24.44) | 2.80 |
| Authors | Studies |
|---|---|
| Akizawa, T; Hayasaki, T; Hayashi, Y; Matsuda, Y; Nobori, K; Yamamoto, H | 3 |
| Akizawa, T; Fujikawa, R; Fujioka, M; Nagao, Y | 1 |
| Kaiser, A; Kapsa, S; Lentini, S; Matsuno, K; van der Mey, D | 1 |
| Kittikulsuth, W; Li, L; Morisawa, N; Nakano, D; Nishiyama, A; Ohsaki, H; Suzuki, N; Yamamoto, M; Zhang, A | 1 |
| Markham, A | 1 |
| Agoro, R; Allen, MR; Atkins, GJ; Broxmeyer, HE; Capitano, ML; Clinkenbeard, EL; Ni, P; Noonan, ML; Prideaux, M; Sacks, SA; Swallow, EA; Thompson, WR; Wheeler, JA; White, KE | 1 |
| Akizawa, T; Hayasaki, T; Hayashi, Y; Matsuda, Y; Nobori, K; Taki, K; Yamamoto, H | 1 |
| Akizawa, T; Hirakata, H; Koretomo, R; Maeda, K; Nangaku, M; Yamada, O; Yamaguchi, T | 1 |
| Fukui, K; Nangaku, M; Tanaka, T | 1 |
| Akbaba, M; Beck, H; Ergüden, JK; Flamme, I; Hartung, IV; Jeske, M; Karig, G; Keldenich, J; Militzer, HC; Oehme, F; Stoll, F; Thede, K; Thuss, U | 1 |
| Arens, ER; Böttcher, M; Kaiser, A; Kubitza, D; Lentini, S; Thuss, U; van der Mey, D; Wensing, G | 1 |
| Gu, J; Jiang, Z; Li, Z; Wu, Y; You, Q; Zhang, X | 1 |
| Akizawa, T; Arai, M; Hirakata, H; Koretomo, R; Matsui, A; Nangaku, M; Yamaguchi, T | 1 |
| Akizawa, T; Bernhardt, T; Berns, JS; Iekushi, K; Krueger, T; Macdougall, IC; Staedtler, G; Taguchi, M | 1 |
| Akizawa, T; Arai, M; Hirakata, H; Koretomo, R; Maeda, K; Miyazawa, Y; Nangaku, M; Yamaguchi, T | 1 |
| Akizawa, T; Iekushi, K; Matsuda, Y; Taguchi, M; Yamada, T; Yamamoto, H | 2 |
| Akizawa, T; Bernhardt, T; Berns, JS; Iekushi, K; Macdougall, IC; Taguchi, M; Yamamoto, H | 1 |
| Ajimi, S; Aso, S; Furukawa, K; Hasegawa, R; Hoshuyama, S; Kikuchi, J; Koga, T; Kusune, Y; Miyata, K; Yoshida, T | 1 |
| Clissa, C; Finelli, C; Stanzani, M | 1 |
| Forni, GL; Fucile, C; Marini, V; Martelli, A; Mattioli, F; Milano, G; Perrotta, S; Pinto, V; Puntoni, M; Robbiano, L | 1 |
| Chen, CH; Shu, KH; Yang, Y | 1 |
| Ellinghaus, P; Flamme, I; Jeske, M; Keldenich, J; Oehme, F; Thuss, U | 1 |
| Cappellini, MD; Chan, LL; El-Alfy, M; El-Ali, A; Giraudier, S; Han, J; Lai, Y; Porter, JB; Viprakasit, V | 1 |
| Cai, J; Duan, Q; Huang, H; Liao, C; Liu, Z; Mao, X; Qi, J; Xia, K; Xiao, Y; Yang, T | 1 |
| Block, GA; Fishbane, S; Locatelli, F; Macdougall, IC | 1 |
| Gupta, N; Wish, JB | 1 |
| Ahl, PL; Arseni, B; Battistini, L; Bonitz, S; Campo, S; Carminati, P; D'Alessio, V; De Santis, R; Di Mitri, D; Lu, R; Mannino, R; Ngoje, J; Rossi, S; Ruggiero, V | 1 |
| Bagust, A; Boland, A; Chu, P; Dickson, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Kirkham, J; McLeod, C; Modell, B; Olujohungbe, A; Telfer, P; Walley, T | 1 |
| Imran, F; Phatak, P | 1 |
| Bergmann, AK; Braunstein, J; Chirnomas, D; Finkelstein, Y; Grant, FD; Neufeld, EJ; Paley, C; Pereira, L; Shannon, M; Smith, AL | 1 |
| Cappellini, MD; Clark, J; Galanello, R; Habr, D; Lawniczek, T; Piga, A; Porter, JB; Taher, A; Vichinsky, E | 1 |
| Cappellini, MD; Taher, A | 1 |
| Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, M; Gattermann, N; Giraudier, S; Habr, D; Kattamis, A; Lee, JW; Li, CK; Lin, KH; Porter, J; Rose, C; Roubert, B; Seymour, JF; Taher, A; Thein, SL; Viprakasit, V | 1 |
| Porter, JB | 1 |
| Fujita, T; Haba, R; Nishiuchi, T; Ohnishi, H; Okutani, Y; Yoshida, K | 1 |
| Beris, P; Domokos, G; Forni, GL; Habr, D; Lin, KH; Porter, JB; Roubert, B; Taher, A; Thein, SL | 1 |
| Hayashi, H; Maeda, H; Naoe, T; Ohashi, H; Saito, H; Tomita, A | 1 |
| Barton, JC | 1 |
| Ozawa, K | 1 |
| Ohyashiki, K | 1 |
| Müller, M; Rapoport, S | 1 |
| Crespeigne, N; Decoster, G; Dodion, P; Gerard, B; Kenis, Y; Lambert, M; Nicaise, C; Rozencweig, M | 1 |
9 review(s) available for triazoles and Anemia
| Article | Year |
|---|---|
Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
Topics: Anemia; Erythropoietin; Hematinics; Humans; N-substituted Glycines; Prolyl-Hydroxylase Inhibitors; Pyridines; Renal Insufficiency, Chronic; Triazoles | 2022 |
Enarodustat: First Approval.
Topics: Anemia; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Molecular Structure; N-substituted Glycines; Prolyl-Hydroxylase Inhibitors; Pyridines; Renal Insufficiency, Chronic; Republic of Korea; Triazoles; United States | 2021 |
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.
Topics: Anemia; Animals; Barbiturates; Blood Pressure; Disease Models, Animal; Drug Design; Drug Interactions; Glycine; Hepcidins; Humans; Hypoxia-Inducible Factor 1; Inflammation; Isoquinolines; Kidney Failure, Chronic; Picolinic Acids; Protein Domains; Pyrazoles; Triazoles | 2017 |
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Topics: Anemia; Barbiturates; Clinical Trials as Topic; Enzyme Inhibitors; Erythropoietin; Glycine; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Isoquinolines; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2017 |
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemosiderosis; Humans; Iron Chelating Agents; Pyridones; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Topics: Adolescent; Adult; Anemia; Benzoates; Child; Child, Preschool; Creatinine; Deferasirox; Drug Administration Schedule; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2009 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
16 trial(s) available for triazoles and Anemia
| Article | Year |
|---|---|
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Topics: Aged; Aged, 80 and over; Anemia; Female; Hematinics; Humans; Male; Middle Aged; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2021 |
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Topics: Aged; Aged, 80 and over; Anemia; Female; Humans; Male; Middle Aged; Pyrazoles; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2021 |
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Topics: Administration, Oral; Adult; Anemia; Area Under Curve; Calcium; Cross-Over Studies; Dietary Supplements; Drug Administration Schedule; Drug Interactions; Erythropoietin; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Iron; Male; Middle Aged; Pyrazoles; Time Factors; Triazoles; Young Adult | 2020 |
Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study.
Topics: Aged; Aged, 80 and over; Anemia; Female; Humans; Japan; Male; Middle Aged; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2021 |
Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study.
Topics: Anemia; Erythropoietin; Hematinics; Hemoglobins; Humans; Japan; Peritoneal Dialysis; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2022 |
First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Topics: Administration, Oral; Adult; Anemia; Area Under Curve; Erythropoietin; Half-Life; Healthy Volunteers; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Prolyl-Hydroxylase Inhibitors; Proof of Concept Study; Pyrazoles; Renal Insufficiency, Chronic; Single-Blind Method; Triazoles; Young Adult | 2018 |
A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Topics: Aged; Aged, 80 and over; Anemia; Dose-Response Relationship, Drug; Double-Blind Method; Erythropoietin; Female; Ferritins; Follow-Up Studies; Hematinics; Hemoglobins; Hepcidins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Japan; Kidney; Male; Middle Aged; N-substituted Glycines; Placebos; Pyridines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles | 2019 |
Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Darbepoetin alfa; Drug Administration Schedule; Epoetin Alfa; Female; Hematinics; Hemoglobins; Humans; Long-Term Care; Male; Middle Aged; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles | 2019 |
Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
Topics: Aged; Anemia; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Ferritins; Hemoglobins; Hepcidins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Middle Aged; N-substituted Glycines; Pyridines; Renal Dialysis; Renal Insufficiency, Chronic; Triazoles | 2019 |
Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
Topics: Anemia; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematinics; Humans; Japan; Male; Middle Aged; Prospective Studies; Pyrazoles; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2019 |
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
Topics: Adult; Anemia; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hematinics; Humans; Male; Practice Guidelines as Topic; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles | 2019 |
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Basic Helix-Loop-Helix Transcription Factors; Double-Blind Method; Female; Hematinics; Hemoglobins; Hepcidins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Iron; Male; Middle Aged; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2019 |
Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
Topics: Anemia; Benzoates; Biomarkers; Deferasirox; Female; Ferritins; Follow-Up Studies; Humans; Iron; Iron Overload; Male; Transferrin; Triazoles | 2016 |
Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
Topics: Adolescent; Adult; Anemia; Benzoates; Biological Availability; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Pharmacogenetics; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2009 |
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Middle Aged; Prospective Studies; Thalassemia; Tissue Distribution; Triazoles; Young Adult | 2010 |
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Topics: Adolescent; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
20 other study(ies) available for triazoles and Anemia
| Article | Year |
|---|---|
Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
Topics: Acute Kidney Injury; Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hypoxia-Inducible Factor 1; Male; Mice, Inbred C57BL; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Triazoles | 2020 |
The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
Topics: Anemia; Animals; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Mice; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2021 |
Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
Topics: Anemia; Hemoglobins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Japan; N-substituted Glycines; Pyridines; Renal Dialysis; Renal Insufficiency, Chronic; Triazoles | 2022 |
Enarodustat to treat anemia in chronic kidney disease.
Topics: Anemia; Erythropoietin; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; N-substituted Glycines; Pyridines; Renal Insufficiency, Chronic; Triazoles | 2021 |
Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
Topics: Anemia; Animals; Binding Sites; Cell Line, Tumor; Drug Discovery; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Kidney Diseases; Mice; Molecular Structure; Protein Binding; Protein Conformation; Pyrazoles; Structure-Activity Relationship; Triazoles | 2018 |
Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
Topics: Administration, Oral; Anemia; Animals; Cisplatin; Click Chemistry; Erythropoietin; Female; Fluorescence Polarization; Glycine; Hemoglobins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Prolyl-Hydroxylase Inhibitors; Rats, Sprague-Dawley; Structure-Activity Relationship; Triazoles | 2018 |
Combined repeated-dose and reproductive/developmental toxicity screening test of 3-amino-5-mercapto-1,2,4-triazole in rats.
Topics: Anemia; Animals; Body Weight; Dose-Response Relationship, Drug; Eating; Female; Hepatocytes; Hypertrophy; Kidney Tubules; Litter Size; Male; No-Observed-Adverse-Effect Level; Organ Size; Pituitary Gland; Pregnancy; Rats; Rats, Sprague-Dawley; Reproduction; Structure-Activity Relationship; Thyroid Gland; Toxicity Tests; Triazoles | 2013 |
[The role of iron metabolism in myelodysplastic syndromes].
Topics: Anemia; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Triazoles | 2014 |
Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzoates; Child; Child, Preschool; Chromatography, High Pressure Liquid; Deferasirox; Female; Genotype; Glucuronosyltransferase; Humans; Iron Chelating Agents; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Risk Factors; Sex Factors; Treatment Outcome; Triazoles; Young Adult | 2015 |
Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Topics: Administration, Oral; Adult; Aged; Anemia; Benzoates; Chelation Therapy; Deferasirox; Female; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
Topics: Anemia; Animals; Erythropoietin; Female; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Macaca fascicularis; Male; Pyrazoles; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Triazoles; Up-Regulation | 2014 |
Inhibition of BET bromodomain improves anemia in APC
Topics: Adenomatous Polyposis Coli Protein; Anemia; Animals; Azepines; Disease Models, Animal; Erythrocyte Indices; Hematocrit; Mice; Mice, Transgenic; Mutation; Nuclear Proteins; Triazoles | 2017 |
Efficacy of a nanocochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease.
Topics: Administration, Oral; Anemia; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokines; Disease Models, Animal; Drug Compounding; Female; Graft vs Host Disease; Hematologic Tests; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Nanocapsules; Time Factors; Triazoles | 2008 |
Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
Topics: Administration, Oral; Anemia; Benzoates; Cost-Benefit Analysis; Deferasirox; Drug Costs; Economics, Pharmaceutical; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Medication Adherence; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2009 |
Deferasirox (Exjade) for the treatment of iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Rare Diseases; Thalassemia; Triazoles | 2009 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Overload; Pyridones; Triazoles | 2009 |
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.
Topics: Aged; Anemia; Benzoates; Chronic Disease; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Radiography; Thrombocytopenia; Transfusion Reaction; Triazoles | 2010 |
Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics.
Topics: Anemia; Benzoates; Biomarkers; Computer Simulation; Deferasirox; Female; Ferritins; Hemochromatosis; Hemosiderin; Hepatitis C, Chronic; Humans; Iron; Iron Chelating Agents; Iron Overload; Japan; Kinetics; Liver; Male; Middle Aged; Models, Biological; Triazoles | 2012 |
CO2 formation from formate in red blood cells.
Topics: Anemia; Animals; Azides; Carbon Dioxide; Catalase; Cyanides; Cytosine Nucleotides; Erythrocyte Aging; Erythrocytes; Formates; Hydrogen; Hydrogen Peroxide; Rabbits; Reticulocytes; Triazoles | 1967 |
Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Triazoles | 1986 |